troglitazone and Polycystic Ovarian Syndrome studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Research Excerpts

Excerpt	Relevance	Reference
" Because troglitazone (Tgz) improves both hormonal profiles and insulin sensitivity, we tested whether Tgz treatment ameliorates endothelial function in these patients."	9.10	Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. ( Baron, AD; Hook, G; Paradisi, G; Shepard, MK; Steinberg, HO, 2003)
"To determine whether amelioration of insulin resistance in polycystic ovary syndrome (PCOS) with the insulin sensitizer troglitazone (TGZ) decreases circulating adrenal androgens (AAs), as reflected by DHEAS levels."	9.10	Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. ( Azziz, R; Ehrmann, DA; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003)
"We hypothesized that the administration of troglitazone (TGZ), an insulin-sensitizing agent of the thiazolidinedione class, would improve dyslipidemia associated with insulin resistance in polycystic ovary syndrome (PCOS)."	9.10	Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. ( Azziz, R; Ehrmann, D; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003)
"To investigate the effect of troglitazone, a new antidiabetic agent that improves insulin resistance, on endocrine, metabolic, and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome (PCOS)."	9.09	Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. ( Hasegawa, I; Kurabayashi, T; Murakawa, H; Suzuki, M; Tanaka, K; Yamamoto, Y, 1999)
"We hypothesized that the administration of troglitazone, an insulin-sensitizing agent of the thiazolidinedione class, would improve the ovulatory dysfunction, hirsutism, hyperandrogenemia, and hyperinsulinemia of polycystic ovary syndrome (PCOS) patients."	9.09	Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. ( Azziz, R; Ehrmann, D; Fereshetian, AG; Ghazzi, MN; Hanley, R; Legro, RS; O'Keefe, M; Whitcomb, RW, 2001)
"Metformin is an effective treatment for anovulation in women with PCOS."	8.82	Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. ( Flight, IH; Lord, JM; Norman, RJ, 2003)
" Troglitazone, one of the thiazolidinediones, improves not only insulin sensitivity but also hyperandrogenism and ovulatory function."	8.80	[Troglitazone for treatment of polycystic ovary syndrome]. ( Iwamoto, Y; Sanaka, M, 2000)
" Before and after treatment with troglitazone (400 mg daily for 12 weeks), all had 1) a GnRH agonist (leuprolide) test, 2) a 75-g oral glucose tolerance test, 3) a frequently sampled iv glucose tolerance test to determine the insulin sensitivity index and the acute insulin response to glucose, 4) an oscillatory glucose infusion to assess the ability of the beta-cell to entrain to glucose as quantitated by the normalized spectral power for the insulin secretion rate, and 5) measures of fibrinolytic capacity [plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator]."	7.69	Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. ( Cavaghan, MK; Ehrmann, DA; Imperial, J; Polonsky, KS; Rosenfield, RL; Schneider, DJ; Sobel, BE, 1997)
" Because troglitazone (Tgz) improves both hormonal profiles and insulin sensitivity, we tested whether Tgz treatment ameliorates endothelial function in these patients."	5.10	Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. ( Baron, AD; Hook, G; Paradisi, G; Shepard, MK; Steinberg, HO, 2003)
"To determine whether amelioration of insulin resistance in polycystic ovary syndrome (PCOS) with the insulin sensitizer troglitazone (TGZ) decreases circulating adrenal androgens (AAs), as reflected by DHEAS levels."	5.10	Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. ( Azziz, R; Ehrmann, DA; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003)
"We hypothesized that the administration of troglitazone (TGZ), an insulin-sensitizing agent of the thiazolidinedione class, would improve dyslipidemia associated with insulin resistance in polycystic ovary syndrome (PCOS)."	5.10	Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. ( Azziz, R; Ehrmann, D; Fereshetian, AG; Ghazzi, MN; Legro, RS; O'Keefe, M, 2003)
"To investigate the effect of troglitazone, a new antidiabetic agent that improves insulin resistance, on endocrine, metabolic, and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome (PCOS)."	5.09	Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. ( Hasegawa, I; Kurabayashi, T; Murakawa, H; Suzuki, M; Tanaka, K; Yamamoto, Y, 1999)
"We hypothesized that the administration of troglitazone, an insulin-sensitizing agent of the thiazolidinedione class, would improve the ovulatory dysfunction, hirsutism, hyperandrogenemia, and hyperinsulinemia of polycystic ovary syndrome (PCOS) patients."	5.09	Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. ( Azziz, R; Ehrmann, D; Fereshetian, AG; Ghazzi, MN; Hanley, R; Legro, RS; O'Keefe, M; Whitcomb, RW, 2001)
"Metformin is an effective treatment for anovulation in women with PCOS."	4.82	Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. ( Flight, IH; Lord, JM; Norman, RJ, 2003)
" Key terms used were thiazolidinediones, troglitazone, rosiglitazone, pioglitazone, polycystic ovary syndrome, and PCOS."	4.82	Thiazolidinediones for treatment of polycystic ovary syndrome. ( Fugate, SE; Stout, DL, 2005)
" Troglitazone, one of the thiazolidinediones, improves not only insulin sensitivity but also hyperandrogenism and ovulatory function."	4.80	[Troglitazone for treatment of polycystic ovary syndrome]. ( Iwamoto, Y; Sanaka, M, 2000)
" Before and after treatment with troglitazone (400 mg daily for 12 weeks), all had 1) a GnRH agonist (leuprolide) test, 2) a 75-g oral glucose tolerance test, 3) a frequently sampled iv glucose tolerance test to determine the insulin sensitivity index and the acute insulin response to glucose, 4) an oscillatory glucose infusion to assess the ability of the beta-cell to entrain to glucose as quantitated by the normalized spectral power for the insulin secretion rate, and 5) measures of fibrinolytic capacity [plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator]."	3.69	Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. ( Cavaghan, MK; Ehrmann, DA; Imperial, J; Polonsky, KS; Rosenfield, RL; Schneider, DJ; Sobel, BE, 1997)
" However, a significant proportion of women with PCOS fail to ovulate with the use of standard dosage of CC and are called CC-resistant PCOS."	2.42	Minireview: Up-date management of non responder to clomiphene citrate in polycystic ovary syndrome. ( Abd el-Aal, G; Abdel-Kareem, O; Amin, M; Maruo, T; Moriyama, T; Takekida, S, 2003)
"Insulin resistance is a common feature of both polycystic ovary syndrome (PCOS) and non-insulin-dependent diabetes mellitus (NIDDM); however, the persistent reproductive disturbances appear to be limited to the former, suggesting that insulin resistance in the ovary itself may confer this susceptibility."	1.32	Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. ( Erkkola, R; Liu, JX; Mäkinen, M; Pöllänen, P; Sallinen, K; Wu, XK; Zhou, SY, 2003)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	10 (35.71)	18.2507
2000's	18 (64.29)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679]	Phase 4	30 participants (Actual)	Interventional	2003-01-31	Completed
Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488]	Phase 4	50 participants (Actual)	Interventional	2013-09-30	Completed
Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome[NCT00784615]		80 participants (Anticipated)	Observational	2007-12-31	Recruiting
Anxiety and Sexual Malfunction in Infertile Polycystic Ovarian Syndrome Patients[NCT05056272]		128 participants (Anticipated)	Observational	2022-01-01	Recruiting
The Impact of Continuous Aerobic Exercise and High-Intensity Interval Training on Reproductive Outcomes in Polycystic Ovary Syndrome: A Pilot Randomized Controlled Trial.[NCT03362918]		60 participants (Actual)	Interventional	2018-01-01	Completed
Adipose Tissue Angiogenesis in Polycystic Ovary Syndrome (PCOS)[NCT01745471]		36 participants (Anticipated)	Observational	2012-12-06	Active, not recruiting
The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).[NCT01588873]	Phase 4	42 participants (Anticipated)	Interventional	2012-04-30	Recruiting
A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471]		45 participants (Anticipated)	Observational	2021-06-30	Not yet recruiting
[NCT01626443]	Phase 4	46 participants (Actual)	Interventional	2014-01-31	Completed
The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial[NCT02491333]	Phase 3	342 participants (Actual)	Interventional	2015-08-31	Completed
Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial[NCT02523898]	Phase 2	388 participants (Anticipated)	Interventional	2015-11-30	Enrolling by invitation
Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851]		90 participants (Anticipated)	Interventional	2015-05-07	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
[Treatment of PCOS without IVF: weight loss, insulin-sensitizing agents]. Journal de gynecologie, obstetrique et biologie de la reproduction, 2003, Volume: 32, Issue:3 Pt 2 Topics: Acarbose; Chromans; Enzyme Inhibitors; Female; Glucose Intolerance; Glucosidases; Humans; Hypoglycem	2003
Insulin sensitizers for polycystic ovary syndrome. Clinical obstetrics and gynecology, 2003, Volume: 46, Issue:2 Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndr	2003
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. The Cochrane database of systematic reviews, 2003, Issue:3 Topics: Anovulation; Chromans; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Induction	2003
Minireview: Up-date management of non responder to clomiphene citrate in polycystic ovary syndrome. The Kobe journal of medical sciences, 2003, Volume: 49, Issue:3-4 Topics: Anovulation; Chromans; Clomiphene; Drug Resistance; Drug Therapy, Combination; Female; Gynecologic S	2003
[Insulin resistance in polycystic ovary syndrome]. Wiener klinische Wochenschrift, 2003, Dec-15, Volume: 115, Issue:23 Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as	2003
Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy, 2005, Volume: 25, Issue:2 Topics: Adult; Chromans; Clinical Trials as Topic; Clomiphene; Contraceptives, Oral; Female; Fertility Agent	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Polycystic ovary syndrome. The New England journal of medicine, 2005, Mar-24, Volume: 352, Issue:12 Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet	2005
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Seminars in reproductive endocrinology, 1997, Volume: 15, Issue:2 Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl	1997
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Seminars in reproductive endocrinology, 1997, Volume: 15, Issue:2 Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl	1997
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Seminars in reproductive endocrinology, 1997, Volume: 15, Issue:2 Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl	1997
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Seminars in reproductive endocrinology, 1997, Volume: 15, Issue:2 Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl	1997
Treatment of hyperinsulinaemia in polycystic ovary syndrome? Human reproduction (Oxford, England), 1998, Volume: 13, Issue:1 Topics: Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Polycystic Ova	1998
Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options? Journal of endocrinological investigation, 1998, Volume: 21, Issue:9 Topics: Chromans; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome	1998
[Troglitazone for treatment of polycystic ovary syndrome]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:2 Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Polycystic Ovary Syndrome; Thiazo	2000
The polycystic ovary syndrome: treatment with insulin sensitizing agents. Diabetes, obesity & metabolism, 1999, Volume: 1, Issue:3 Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Obesity; Ovar	1999
[Polycystic ovary syndrome: treatment with insulin-sensitizing agents]. Annales d'endocrinologie, 2002, Volume: 63, Issue:1 Topics: Androgens; Chromans; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing	2002

Article	Year
Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:2 Topics: Blood Glucose; Blood Pressure; Chromans; Endothelium, Vascular; Female; Humans; Hyperandrogenism; Hy	2003
Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertility and sterility, 2003, Volume: 79, Issue:4 Topics: Adrenal Glands; Adult; Blood Glucose; Chromans; Dehydroepiandrosterone Sulfate; Dose-Response Relati	2003
Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:11 Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Chromans; Female; Humans; Hyperlipidemias; Hypoglycemic A	2003
Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. Journal of clinical epidemiology, 2004, Volume: 57, Issue:12 Topics: Adult; Chromans; Factor Analysis, Statistical; Female; Health Status; Humans; Polycystic Ovary Syndr	2004
The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:9 Topics: Adult; Body Mass Index; Chromans; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Double-Bli	1996
Leptin concentrations in the polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:6 Topics: Adult; Body Mass Index; Chromans; Double-Blind Method; Female; Humans; Hyperinsulinism; Hypoglycemic	1997
Treatment of hyperinsulinaemia in polycystic ovary syndrome? Human reproduction (Oxford, England), 1998, Volume: 13, Issue:1 Topics: Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Polycystic Ova	1998
Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertility and sterility, 1999, Volume: 71, Issue:2 Topics: Adult; Androgens; Chromans; Female; Gonadotropins; Hormones; Humans; Hypoglycemic Agents; Insulin; I	1999
Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:4 Topics: Adult; Androgens; Blood Glucose; Chromans; Dose-Response Relationship, Drug; Double-Blind Method; Fe	2001
Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:4 Topics: Adult; Androgens; Blood Glucose; Chromans; Dose-Response Relationship, Drug; Double-Blind Method; Fe	2001
Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:4 Topics: Adult; Androgens; Blood Glucose; Chromans; Dose-Response Relationship, Drug; Double-Blind Method; Fe	2001
Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:4 Topics: Adult; Androgens; Blood Glucose; Chromans; Dose-Response Relationship, Drug; Double-Blind Method; Fe	2001

Article	Year
Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertility and sterility, 2003, Volume: 80, Issue:4 Topics: Adult; Cells, Cultured; Chromans; DNA; Female; Glucose; Granulosa Cells; Humans; Insulin; Insulin Re	2003
Insulin-lowering agents inhibit synthesis of testosterone in ovaries of DHEA-induced PCOS rats. Gynecologic and obstetric investigation, 2006, Volume: 61, Issue:4 Topics: 17-Hydroxysteroid Dehydrogenases; Adjuvants, Immunologic; Animals; Chromans; Dehydroepiandrosterone;	2006
Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:7 Topics: Adult; Androgens; Chromans; Female; Fibrinolysis; Glucose; Glucose Tolerance Test; Gonadotropins; Hu	1997
Insulin-sensitising agents in polycystic-ovary syndrome. Lancet (London, England), 1998, Jan-31, Volume: 351, Issue:9099 Topics: Chromans; Controlled Clinical Trials as Topic; Female; Humans; Hyperinsulinism; Hypoglycemic Agents;	1998
High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Human reproduction (Oxford, England), 1999, Volume: 14, Issue:11 Topics: Adult; Body Temperature; Chromans; Clomiphene; Drug Resistance; Female; Humans; Infertility, Female;	1999
Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome. Annals of the New York Academy of Sciences, 2000, Volume: 900 Topics: Androgen Antagonists; Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin;	2000
Troglitazone use in polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism, 2001, Volume: 86, Issue:10 Topics: Chromans; Clinical Trials as Topic; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Polycystic	2001

troglitazone and Polycystic Ovarian Syndrome

Research Excerpts

Research

Studies (28)

Authors

Clinical Trials (12)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Paradisi, G	1
Steinberg, HO	1
Shepard, MK	1
Hook, G	1
Baron, AD	1
Azziz, R	4
Ehrmann, DA	4
Legro, RS	3
Fereshetian, AG	3
O'Keefe, M	3
Ghazzi, MN	3
Pugeat, M	1
Baillargeon, JP	1
Iuorno, MJ	2
Nestler, JE	3
Lord, JM	1
Flight, IH	1
Norman, RJ	1
Wu, XK	1
Zhou, SY	1
Liu, JX	1
Pöllänen, P	1
Sallinen, K	1
Mäkinen, M	1
Erkkola, R	1
Ehrmann, D	2
Amin, M	1
Abdel-Kareem, O	1
Takekida, S	1
Moriyama, T	1
Abd el-Aal, G	1
Maruo, T	1
Schröder, AK	1
Tauchert, S	1
Ortmann, O	1
Diedrich, K	1
Weiss, JM	1
Guyatt, G	1
Weaver, B	1
Cronin, L	1
Dooley, JA	1
Stout, DL	1
Fugate, SE	1
Misugi, T	1
Ozaki, K	1
El Beltagy, K	1
Tokuyama, O	1
Honda, K	1
Ishiko, O	1
Dunaif, A	2
Scott, D	1
Finegood, D	1
Quintana, B	1
Whitcomb, R	1
Mantzoros, CS	1
Flier, JS	1
Schneider, DJ	1
Sobel, BE	1
Cavaghan, MK	1
Imperial, J	1
Rosenfield, RL	1
Polonsky, KS	1
van Montfrans, JM	1
van Hooff, MH	1
Hompes, PG	1
Lambalk, CB	1
Sattar, N	1
Hopkinson, ZE	1
Greer, IA	1
Hasegawa, I	1
Murakawa, H	1
Suzuki, M	1
Yamamoto, Y	1
Kurabayashi, T	1
Tanaka, K	1
Mitwally, MF	1
Kuscu, NK	1
Yalcinkaya, TM	1
Sanaka, M	1
Iwamoto, Y	1
Diamanti-Kandarakis, E	1
Zapanti, E	1
Whitcomb, RW	1
Hanley, R	1
Landman, RE	1
Jacobs, TP	1
Laboureau-Soares Barbosa, S	1
Rodien, P	1
Rohmer, V	1